Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against ...

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the ...

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...

Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...

These events underscore Dyadic’s commitment to expanding its global footprint and advancing its mission to revolutionize biomanufacturing with its proprietary C1 and Dapibus™ technology platforms.

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1705993&tp_key=2267a6328b. An archive of the webcast will be available within 24 hours after completion of ...

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene ...

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy ...

Improving patient outcomes, satisfaction and safety while using resources responsibly is foundational to the ever-changing world of kidney health care delivery. Leadership that succeeds clinically and ...

Aiming for the courtroom equivalent of a pin, former collegiate wrestler Mark Emalfarb alleged blue-chip law firms robbed his biotech company of $185 million in vanished market capitalization and $700 ...